Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

SARS-CoV-2 Rebound With and Without Use of COVID-19 Oral Antivirals
Dallas J. Smith, Anastasia S. Lambrou, Pragna Patel
MMWR Morbidity and Mortality Weekly Report (2023) Vol. 72, Iss. 51, pp. 1357-1364
Open Access | Times Cited: 25

Showing 25 citing articles:

The Potential of Peptide-Based Inhibitors in Disrupting Protein–Protein Interactions for Targeted Cancer Therapy
Ana Maria Sardinha Afonso, Carlos Cavaleiro, Miguel A. R. B. Castanho, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 7, pp. 3117-3117
Open Access | Times Cited: 1
Effectiveness of Nirmatrelvir-Ritonavir for the Prevention of COVID-19–Related Hospitalization and Mortality: A Systematic Literature Review
A. Cha-Silva, M. Gavaghan, Tobias Bergroth, et al.
American Journal of Therapeutics (2024) Vol. 31, Iss. 3, pp. e246-e257
Open Access | Times Cited: 5
Does early combination vs. Monotherapy improve clinical outcomes of clinically extremely vulnerable patients with COVID-19? Results from a retrospective propensity-weighted analysis
Maria Mazzitelli, Alberto Enrico Maraolo, Claudia Cozzolino, et al.
European journal of medical research (2024) Vol. 29, Iss. 1
Open Access | Times Cited: 5
Efficacy and safety of antiviral therapies for the treatment of persistent COVID-19 in immunocompromised patients since the Omicron surge: a systematic review
Caroline Hirsch, Nina Kreuzberger, Nicole Skoetz, et al.
Journal of Antimicrobial Chemotherapy (2025)
Open Access
SARS-CoV-2 outbreak in lions, tigers, and hyenas at Denver Zoo
Emily N. Gallichotte, Laura Bashor, Katelyn Erbeck, et al.
mSphere (2025)
Open Access
Nirmatrelvir treatment duration and frequency of COVID-19 rebound
Nathan Sudeep, Noah Kojima, Jeffrey D. Klausner
Antiviral Therapy (2025) Vol. 30, Iss. 1
Open Access
Suspect Screening of Pharmaceuticals and Their Transformation Products (TPs) in Wastewater during COVID-19 Infection Peak: Identification of New TPs and Elevated Risks
Lihua Yu, Yongfeng Lin, Jingjing Li, et al.
Environmental Science & Technology (2025)
Closed Access
Clinical Manifestations of SARS-CoV-2 Infection in Immunocompetent Adults in the Era of Widespread Population Immunity and Omicron Sublineage Viruses
Alexander Shaffer, Eric A. Meyerowitz
Infectious Disease Clinics of North America (2025)
Closed Access
Efficacy of antiviral therapy and disease outcomes in COVID-19 patients previously treated with obinutuzumab for follicular lymphoma
Nobuhiro Okagaki, Seishu Hashimoto, Satoshi N. Nakamura, et al.
Tenri Medical Bulletin (2025)
Open Access
Effects of Nirmatrelvir/ritonavir (paxlovid) on the nervous system: analysis on adverse events released by FDA
Caixia Gao, Zhihui Liu, Zhen Zou, et al.
Expert Opinion on Drug Safety (2025), pp. 1-8
Closed Access
Pharmacologic Treatment and Management of Coronavirus Disease 2019
Amy Hirsch Shumaker, Adarsh Bhimraj
Infectious Disease Clinics of North America (2025)
Closed Access
Kinetics of SARS‐CoV‐2 Shedding in Nursing Home Residents and Staff
Morgan J. Katz, Majerle Reeves, Tiffany G. Harris, et al.
Journal of the American Geriatrics Society (2025)
Open Access
Paxlovid for nonhospitalized patients with COVID‐19
Fatima Johari, Rajesh Verma
Academic Emergency Medicine (2024) Vol. 31, Iss. 6, pp. 621-623
Closed Access | Times Cited: 2
Antiviral properties of milk proteins and peptides against SARS-COV-2: A review
Parminder Singh, Janak Dhakal, Pavan Kumar
Journal of Functional Foods (2024) Vol. 117, pp. 106237-106237
Open Access | Times Cited: 2
Clinical rebound after treatment with nirmatrelvir/ritonavir in COVID-19
Daniel M. Camp, Matthew Caputo, Fabiola Moreno Echevarria, et al.
BMC Infectious Diseases (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 1
Differences in COVID-19 Outpatient Antiviral Treatment Among Adults Aged ≥65 Years by Age Group — National Patient-Centered Clinical Research Network, United States, April 2022–September 2023
Claire M. Quinlan, Melisa M. Shah, Carol DeSantis, et al.
MMWR Morbidity and Mortality Weekly Report (2024) Vol. 73, Iss. 39, pp. 876-882
Open Access | Times Cited: 1
COVID-19 Therapeutics for Nonhospitalized Older Adults
Pragna Patel, David E. Wentworth, Demetre Daskalakis
JAMA (2024) Vol. 332, Iss. 18, pp. 1511-1511
Closed Access | Times Cited: 1
Virologic Response and Safety of Ibuzatrelvir, a Novel SARS-CoV-2 Antiviral, in Adults With COVID-19
Mahta Mortezavi, Abigail Sloan, Ravi Shankar Prasad Singh, et al.
Clinical Infectious Diseases (2024)
Open Access | Times Cited: 1
Viral SARS-CoV-2 Rebound Rates in Linked Commercial Pharmacy-Based Testing and Health Care Claims
Scott P. Kelly, Lisa M. McEwen, Magnus Isaksson, et al.
Open Forum Infectious Diseases (2024) Vol. 11, Iss. 6
Open Access
COVID-19 clinical rebound after treatment with nirmatrelvir/ritonavir
Daniel M. Camp, Matthew Caputo, Fabiola Moreno Echevarria, et al.
Research Square (Research Square) (2024)
Open Access
SARS-CoV-2 outbreak in lions, tigers and hyenas at Denver Zoo
Emily N. Gallichotte, Laura Bashor, Katelyn Erbeck, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Kinetics of SARS-CoV-2 Shedding in Nursing Home Residents and Staff
Morgan J. Katz, Majerle Reeves, Tiffany G. Harris, et al.
(2024)
Closed Access
EFFECTS OF ANTIVIRAL THERAPEUTIC DRUGS FOR SARS-COV-2 ON TREATMENT OUTCOMES AND CLINICAL PARAMETERS
Abdul Bari, Atiqullah Sarwari, Mohammad Hassan, et al.
Eurasian Journal of Ecology (2024) Vol. 79, Iss. 2, pp. 136-146
Open Access
Disparate SARS-CoV-2 infection outcomes abound, but what makes SARS-CoV-2 bound for rebound?
Timothy P. Sheahan
The Journal of Infectious Diseases (2024)
Open Access
Independent FDA Analyses of Nirmatrelvir/Ritonavir Resistance in the Phase 2/3 Trials EPIC-HR and EPIC-SR
Jonathan Rawson, Eric Donaldson, Julian J. O’Rear, et al.
Clinical Infectious Diseases (2024)
Open Access
Page 1

Scroll to top